Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

European Urology

Volumn 53, Issue 5, 2008, Pages 992-1002

  Fernandez Gomez, Jesus ^a   Solsona, Eduardo ^b   Unda, Miguel ^c   Martinez Piñeiro, Luis ^d   Gonzalez, Marcelino ^e   Hernandez, Rafael ^f   Madero, Rosario ^d   Ojea, Antonio ^g   Pertusa, Carlos ^h   Rodriguez Molina, Jesus ⁱ   Camacho, Jose Emilio ^j   Isorna, Santiago ^k   Rabadan, Mariano ^l   Astobieta, Ander ^m   Montesinos, Manuel ⁿ   Muntañola, Pedro ^o   Gimeno, Anabel ^p   Blas, Miguel ^q   Martinez Piñeiro, Jose Antonio ^d  

^a UNIVERSITY OF OVIEDO   (Spain)

^b IVO   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL XERAL CALDE   (Spain)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL DE JEREZ   (Spain)

^k HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^l HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^m HOSPITAL DE GALDAKAO   (Spain)

ⁿ Universidad Pública de Navarra   (Spain)

^o HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^p La Mancha Centro General Hospital   (Spain)

^q HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Disease progression; Recurrence

Indexed keywords

BCG VACCINE; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CYSTOSCOPY; DRUG DOSE COMPARISON; FEMALE; GENDER; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; RECURRENCE RISK;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 41149144274     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.10.006     Document Type: Article

References (42)

1. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Algaba F., and Vicente-Rodriquez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 163 (2000) 680-684
2. van der Meijden A.P., and Sylvester R.J. BCG immunotherapy for superficial bladder cancer: an overview of the past, the present and the future. EAU Update Series 1 (2003) 80-86
3. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
4. Sylvester R.J., van der Meijden A.P.M., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
5. Saint F., Salomon L., Quintela R., et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 43 (2003) 351-361
6. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
7. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
8. Takashi M., Wakai K., Hattori T., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 33 (2002) 41-47
9. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
10. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
11. Evans C.P. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer. Eur Urol 52 (2007) 1129-1130
12. Martinez-Piñeiro J.A., Flores N., Isorna S., et al., for CUETO (Club Urológico Español de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
13. Shinka T., Matsumoto M., Ogura H., Hirano A., and Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Int J Urol 4 (1997) 139-143
14. Morales A., Nickel C., and Wilson J.W.L. Dose-response of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J Urol 147 (1992) 1256-1258
15. Mack D., Holtl W., Bassi P., et al. European Organisation Research and Treatment of Cancer Genitourinary. The ablative effect of quarter dose bacillus Guérin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
16. Kumar A., Dubey D., Bansal P., Mandhani A., and Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guérin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 168 (2002) 2232-2235
17. Cheng C.W., Ng M.T., Chan S.Y., and Sun W.H. Low dose adjuvant therapy for superficial bladder cancer literature review. ANZ J Surg 74 (2004) 569-572
18. Ojea A., Nogueira J.L., Solsona E., et al. members of the CUETO Group (Club Urológico Español De Tratamiento Oncologico). A multicenter, randomised prospective trail comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
19. Witjes J.A. What is the optimal BCG dose in non-muscle-invasive bladder cancer?. Eur Urol 52 (2007) 1300-1302
20. Martinez-Piñeiro J.A., Martinez-Piñeiro L., Solsona E., et al., Club Urologico Espanol de Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
21. Solsona E, Gonzalez M, Fernandez JM, Unda M, Bernuy C, Pertusa C, members of CUETO Group Random trial comparing intravesical chemo-induction with MMC to immunotherapy with BCG versus intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Preliminary results of the CUETO Trial no. 93009. Abstract. XIXth Congress of the European Association of Urology, Vienna, 2004.
22. Hurle R., Losa A., Ranieri A., Graziotti P., and Lembo A. Low dose Pasteur bacillus Calmette-Guérin regime in stage T1, grade 3 bladder cancer therapy. J Urol 156 (1996) 1602-1605
23. Lebret T., Gaudez F., Hervé J.M., Barré P., Lugagne P.M., and Botto H. Low dose BCG instillations in the treatment of stage T1 grade 3. Eur Urol 34 (1998) 67-72
24. Saint F., Patard J.J., Maille P., et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 167 (2002) 364-367
25. Akaza H., Hinotsu S., Aso Y., Kakizoe T., and Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75 (1995) 552-559
26. Lundholm C., Norlen B.J., Ekman P., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 56 (1996) 372-376
27. Joudi F.N., Smith B.J., O'Donnell M.A., and Konety B.R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639
28. Losa A., Hurle R., and Lembo A. Low dose Bacillus Calmette-Guérin for carcinoma in situ of the bladder: long-term results. J Urol 163 (2000) 68-72
29. Davis J.W., Sheth S.I., Doviak M.J., and Schellhammer P.F. Superficial bladder carcinoma treated with bacillus Calmette-Guérin: progression-free and disease specific survival with 10-year minimum follow-up. J Urol 167 (2002) 494-501
30. Zlotta A.R., Noel J.C., Fayt I., et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy. J Urol 161 (1999) 792-798
31. Herr H.W., Badalament R.A., Amato D.A., Laudone V.P., Fair W.R., and Whitmore W.F. Superficial bladder cancer treated with Bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J Urol 141 (1989) 22-29
32. Klein E.A., Rogatko A., and Herr H.W. Management of local Bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 147 (1992) 601-605
33. Ovesen H., Horn T., and Steven K. Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histologic response and p53 nuclear accumulation. J Urol 157 (1997) 1655-1659
34. Hurle R., Losa A., Manzetti A., and Lembo A. Intravesical bacillus Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-years follow-up. Urology 54 (1999) 258-263
35. Pansadoro V., Emiliozzi P., de Paula F., Scarpone P., Pansadoro A., and Sternberg C.N. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin: 18-year experience. Urology 59 (2002) 227-231
36. Griffiths T.R.L., Charlton M., Neal D.E., and Powell P.H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guérin without maintenance. J Urol 167 (2002) 2408-2412
37. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45 (2004) 292-296
38. Gattegno B. T1G3 Bladder cancer: conservative management or cystectomy?. Eur Urol 45 (2004) 399-400
39. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
40. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
41. Brausi M., Collette L., Kurth K., et al., EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
42. Nieder A.M., Brausi M., Lamm D., et al. Management of stage t1 tumors of the bladder: International Consensus Panel. Urology 66 Suppl 6A (2005) 108-125